Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 9, 2016 6:00 AM EDT2016 Full Year Guidance Reconfirmed
LAVAL, Quebec, Aug. 9, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015 GAAP EPS Â ($0.88) and Adjusted EPS (non-GAAP) Â $1.40 Cash Flow from Operations of $448 million, an increase of 9% versus the second quarter of 2015Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced second quarter 2016 financial results.
"We continue to make progress towards stabilizing the... More
